高级检索
当前位置: 首页 > 详情页

Liposomal irinotecan+5-FU/LV + bevacizumab for second-line treatment of metastatic colorectal cancer (IRIS): A prospective, multi-center, single-arm clinical study

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE ◇ CPCI(ISTP)

机构: [1]Hebei Med Univ, Hosp 4, Dept Gen Surg 2, Shijiazhuang, Hebei, Peoples R China [2]Shanxi Canc Hosp, Dept Colorectal Surg, Taiyuan, Peoples R China [3]Shanxi Canc Hosp, Dept Gastroenterol, Taiyuan, Peoples R China [4]Jiangxi Canc Hosp, Dept Abdominal Tumor Surg, Nanchang, Jiangxi, Peoples R China [5]Hebei Med Univ, Dept Gen Surg 2, Hosp 4, Shijiazhuang, Hebei, Peoples R China [6]Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China [7]Tianjin Med Univ Canc Inst & Hosp, Dept Colorectal Oncol, Tianjin, Peoples R China [8]Hebei Med Univ, Dept Med Oncol, Hosp 4, Shijiazhuang, Hebei, Peoples R China [9]Hebei Med Univ, Hosp 4, Dept Gastroenterol, Shijiazhuang, Hebei, Peoples R China [10]Tangshan Peoples Hosp, Dept Radiochemotherapy, Tangshan, Peoples R China [11]Hebei Med Univ, Dept Gen Surg, Dept Gen Surg 2, Hosp 2,Hosp 4,Hebei Prov Key Lab Gastrointestinal, Shijiazhuang, Hebei, Peoples R China
出处:
ISSN:
基金:
语种:
被引次数:
WOS:
中科院分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区:
出版当年[2024]版:
Q1 ONCOLOGY
最新[2024]版:
Q1 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Dept Gen Surg 2, Shijiazhuang, Hebei, Peoples R China
通讯机构: [11]Hebei Med Univ, Dept Gen Surg, Dept Gen Surg 2, Hosp 2,Hosp 4,Hebei Prov Key Lab Gastrointestinal, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号